Regeneron has become the first company to get US approval for a gene therapy for congenital hearing loss, after the FDA gave a rapid clearance to its OTOF-targeting medicine Otarmeni. In a remarkable ...

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...

A child known publicly as Baby KJ was celebrated onstage at the twelfth Breakthrough Prize ceremony in Santa Monica last ...

You might like the sound of this news. In a landmark move, the Food and Drug Administration on Thursday approved the first gene therapy for a rare, inherited form of hearing loss. And while these ...

US health officials on Thursday greenlit a first-of-its-kind gene therapy to treat a rare form of hereditary hearing loss, a breakthrough that could pave the way for other such hearing impairment ...

Children born deaf because of a rare condition can now take a drug to restore their hearing after a gene therapy was approved in the U.S., ushering in a new era for the treatment of an inherited form ...

The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss. Subscribe to read this story ad-free Get unlimited access to ad-free ...

The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical ...

This article is part of Examined World, a contemplative series exploring what the sciences reveal about us. Our debates and discussions on technology are currently dominated by artificial intelligence ...

The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss. The drugmaker said it will offer the drug for free to U.S. patients.

Fabry disease is a rare, X-linked genetic lysosomal storage disorder caused by a deficient enzyme called alpha-galactosidase A. Without it, a fatty substance called globotriaosylceramide, or GL-3, ...